ScreenerHero

REVB Revelation Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · revbiosciences.com
0.7522USD-3.20%Mkt Cap: 3.00M $P/E: 0.16

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a pro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap3.00M USD
Enterprise Value-7.75M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.91M USD
Revenue/Share—
Last Price0.7522 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.16
P/E (Forward)-0.26
PEG—
EV/EBITDA0.69
EV/Revenue—
P/S—
P/B0.29
EPS (TTM)4.60
EPS (Forward)-2.89
52W Range
0.75000% of range6.760
52W High6.760 USD
52W Low0.7500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-100.59%
ROA-76.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.27M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-192.81%
Net Debt-10.74M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.08
Current Ratio6.21
Quick Ratio6.11
Book Value/Sh2.58 USD
Cash/Share2.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJan 28, 2026
Analyst Consensus
Rating—
Target (Mean)17.75 USD
Upside (mean)+2259.7%
Target Range16.00 USD – 19.50 USD
16.00+2259.7% to mean19.50
# Analysts2
Ownership
Shares Out.3.98M
Float3.05M
Insiders12.34%
Institutions12.89%
Short Interest
Short Ratio0.0d
Short % Float0.01%
Short % Out.0.01%
Shares Short256
Short (prev mo.)15.39K
Technical
SMA 500.9981 (-24.6%)
SMA 2001.440 (-47.7%)
Beta-0.06
S&P 52W Chg16.45%
Avg Vol (30d)35.58K
Avg Vol (10d)51.21K
Technical Indicators
RSI (14)28.4
MACD-0.0711
MACD Signal-0.0571
MACD Hist.-0.0140
BB Upper1.088 USD
BB Middle0.9033 USD
BB Lower0.7190 USD
BB Width40.80%
ATR (14)0.0563 USD
Vol Ratio (20d)1.11x